Toronto Dominion Bank’s Roivant Sciences ROIV Stock Holding History

Toronto Dominion Bank’s Portfolio ROIV Stock Details ROIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1,600	Closed	-$24.2K	–	2249
2025 Q3	$24.2K	Buy	+1,600	New	+$19.8K	﹤0.01%	1695

Other funds holding ROIV

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Toronto Dominion Bank's ROIV Position: Q1 2026 in Review

Toronto Dominion Bank sold out of Roivant Sciences (ROIV) in Q1 2026, closing a stake of 631,004 shares — an estimated $13.7M sold.

Toronto Dominion Bank first reported a position in ROIV in Q4 2025 and held it in 1 quarter. The position peaked at $13.7M in Q4 2025. 440 funds tracked by Wall St. Rank hold ROIV as of Q1 2026.

Toronto Dominion Bank reported no remaining Roivant Sciences position as of Q1 2026 after selling out during the quarter.
Toronto Dominion Bank sold 631,004 Roivant Sciences shares in Q1 2026, an estimated $13.7M.
Toronto Dominion Bank first reported a position in Roivant Sciences in Q4 2025 and held it in 1 quarter.
Toronto Dominion Bank's Roivant Sciences position peaked at $13.7M in Q4 2025.
440 funds tracked by Wall St. Rank held Roivant Sciences as of Q1 2026.

Based on Toronto Dominion Bank's 13F filing for Q1 2026, filed 15 May 2026.